CONCORDE Trial
CONCORDE is a clinical trial designed to assess recommended phase II dose for a number of DNA damage response inhibitors combined with radiotherapy for patients with non small cell lung cancer who are not suitable for concurrent chemoradiotherapy. As part of the trial blood samples will be collected and analysed as part of the exploratory endpoints at multiple laboratories. Once the trial exploratory analysis is concluded residual samples will be biobanked.
Services
- Ability to recontact
- Data analytics
Existing samples:
- Carcinoma in situ of lung (disorder)
Contact Information
- Email:
- ctru_concorde@leeds.ac.uk
- Address:
-
Leeds Institute of Clinical Trials Research
University of Leeds
Leeds
West Yorkshire
LS2 9JT
England
Last Updated: 03/24/2021
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |